Roche 6 Pill - Search News

Roche, obesity and Zealand

Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

BioPharma Dive · 3d

Roche broadens obesity drug plans with $1.65B Zealand deal

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.

STAT · 3d

Roche partners with Zealand Pharma to push forward obesity drug

Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its obesity pipeline.

1don MSN

Potential Carcinogen Found in 6 Popular Acne Products, Prompting Recall: FDA

The agency announced that after concerns were raised about levels of benzene in products containing benzoyl peroxide, they ...

MedCity News3d

Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity

Milestone payments could bring Copenhagen-based Zealand up to $3.6 billion more ... or overweight with type 2 diabetes. Roche entered the obesity drug chase with its $2.3 billion Carmot ...

12d

Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer ...

Nasdaq11d

Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults

Roche’s shares have risen 30.6% year to date compared with the large ... Xolair is the only FDA-approved drug to reduce allergic reactions in children and adults with one or more food allergies.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results